

16 July 2026

## Emyria to Present at Upcoming Investor and Industry Events

*Emyria invited to present at leading investor and industry events across New South Wales, Victoria, and New Zealand during July and August*

- **TechKnow** – Monday, 27 July (Melbourne) and Wednesday, 29 July (Sydney)
- **Jane Morgan Management Investor Lunch** – Tuesday, 28 July (Sydney)
- **Bioshares Biotech Summit** – 5-7 August (Queenstown, NZ)
- **Armchair After Market Briefing** – 27 August (Melbourne)

**Emyria Limited (ASX: EMD) ("Emyria", or the "Company")**, a leader in delivering evidence-based intensive mental-health care, is pleased to announce that Chief Operating Officer, Mary-Ann Rennie, and Executive Chair, Greg Hutchinson will present at a number of upcoming investor and biotechnology industry events.

The events will provide investors and industry participants with the opportunity to hear from Emyria's management and learn more about the Company's recent Empax clinic rollout progress, as well as other upcoming milestones and strategic priorities.

### **TechKnow – Melbourne & Sydney**

Emyria's Chief Operating Officer, Mary-Ann Rennie will present at TechKnow Invest Roadshow, Australia's largest investment conference for the tech industry, at both the Melbourne and Sydney instalment of the event. TechKnow brings together investors and brokers to exchange ideas and perspectives, and to hear from leaders across the biotech and technology sectors.

#### Melbourne

- Date: Monday, 27 July
- Location: Sofitel Melbourne on Collins
- Time: 2.45pm

#### Sydney

- Date: Wednesday, 29 July
- Location: Swissôtel Sydney
- Time: 9.15am

Registration link and further details can be found [here](#).

### **Jane Morgan Management East Coast Investor Lunch - Sydney**

Greg Hutchinson will present at the upcoming Jane Morgan Management East Coast Investor Lunch, providing investors with the opportunity to hear directly from Management and learn more about the Company's latest developments.

- Date: Tuesday, 28 July
- Location: Establishment Ballroom, 252 George Street, Sydney
- Time: 12:30pm

Registration link and further details can be found [here](#).

## **2026 Bioshares Biotech Summit – New Zealand**

Chief Operating Officer Mary-Ann Rennie will also present at the 2026 Bioshares Biotech Summit, to be held in Queenstown, New Zealand from 5–7 August 2026.

Emyria will participate in the Summit’s “Lightning Round”, where biotechnology companies provide an update on key advances achieved over the past 12 months and upcoming events to watch.

- Date: Friday, 7 August
- Location: QT Hotel, Queensland, New Zealand
- Time: 4.40pm

Registration link and further details can be found [here](#).

## **Armchair After Market Investor Briefing - Melbourne**

Executive Chair Greg Hutchinson will present at an event for ASX-listed biotechs, hosted by Jason Segal, author of the daily ‘Armchair Analyst’ newsletter.

- Date: Thursday, 27 August
- Location: Level 16, 542 Flinders Street, Melbourne
- Time: 3.30pm

Registration link and further details can be found [here](#).

Executive Chair, Greg Hutchinson commented: *“We are pleased to be invited to present at these upcoming industry and investor conferences, which provide a valuable platform to discuss the growing role of evidence-based mental healthcare and Emyria’s position within this evolving sector. We look forward to engaging with investors and industry participants, sharing our progress, and demonstrating how our scalable care model and real-world evidence capabilities are helping improve access to critical mental health treatments for patients across Australia.”*

*This release has been approved by the Board of Emyria.*

**For further information, investment opportunities, or more about Emyria’s approach to mental health treatment, please contact:**

**Greg Hutchinson Executive Chair**

1300 153 355 | [investors@emyria.com](mailto:investors@emyria.com)

For personal use only



**Emyria Limited** develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development:

generates

**Emyria Healthcare:** Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression.

informs

**Emyria Data:** Robust and ethically sourced Real-World Data gathered with patients to improve Emyria's unique therapy and drug development programs.

**Emyria's Pipeline:** New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

#### EMYRIA'S INTERACTIVE INVESTOR HUB

**Investorhub.emyria.com** Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.



**CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS** Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

#### Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown.

The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products' ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy.